Positron system to offer Amyvid PET scans

| | Health Imaging | Molecular Imaging
Positron is using its Attrius system at Caring Heart and Brain Imaging of Manasquan, N.J., which now offers Amyvid PET scans to identify the presence of plaque in the brain, which has been shown to be a precursor to Alzheimer's disease (AD).

Amyvid (Florbetapir F-18 Injection) is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for AD and other causes of cognitive decline.

"We are pleased that our Attrius PET system could possibly help with the identification and management of this disease," stated Joseph Oliverio, chief technology officer and director of PET clinical programs of Positron.


Related Content

PET method offers new insight into inflammation of the brain
New PET imaging method could improve our understanding of long COVID
FDA approves new prostate cancer imaging agent with extended shelf life
New PET study offers insight into how dopamine drives executive function
New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.